Generic TRIMETHOPRIM HYDROCHLORIDE INN entry, pharmaceutical patent expiration information and freedom to operate

Sponsor	Phase
University of California, San Francisco	PHASE4
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE4
University of Pennsylvania	PHASE1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pangea	PRIMSOL	trimethoprim hydrochloride	SOLUTION;ORAL	074973-001	Jan 24, 2000		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pangea	PRIMSOL	trimethoprim hydrochloride	SOLUTION;ORAL	074374-001	Jun 23, 1995		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pangea	PRIMSOL	trimethoprim hydrochloride	SOLUTION;ORAL	074973-001	Jan 24, 2000	5,763,449	⤷ Start Trial
Pangea	PRIMSOL	trimethoprim hydrochloride	SOLUTION;ORAL	074973-001	Jan 24, 2000	5,962,461	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Last updated: September 8, 2026

Trimethoprim hydrochloride is a mature, low-cost antibacterial active ingredient with limited standalone commercial value. Its market is driven by generic oral products, pediatric liquid formulations, and combination products containing sulfamethoxazole and trimethoprim. The active ingredient has no meaningful current composition-of-matter exclusivity, no biosimilar pathway, and limited ability to support premium pricing. Financial performance depends primarily on manufacturing efficiency, supply reliability, hospital contracts, and the commercial position of the finished-dose product.

What is the current market position of trimethoprim hydrochloride?

Trimethoprim hydrochloride is the salt form used in several pharmaceutical formulations of trimethoprim. The drug inhibits bacterial dihydrofolate reductase and is used for urinary tract infections, selected respiratory infections, and other susceptible bacterial infections.

The principal commercial formats are:

Product type	Typical use	Market position
Trimethoprim tablets	Adult urinary tract infections	Generic, low-price market
Trimethoprim oral solution	Pediatric and swallowing-limited patients	Smaller but less commoditized niche
Trimethoprim-sulfamethoxazole tablets	Broad antibacterial use	Larger combination-product market
Trimethoprim-sulfamethoxazole oral suspension	Pediatric and outpatient use	Established generic market
Injectable trimethoprim products	Limited hospital use	Narrow availability by jurisdiction

In the United States, trimethoprim products are generally marketed as abbreviated new drug application products or legacy approved products. The commercial market is fragmented among generic manufacturers and contract manufacturers. No single company has durable control of the active ingredient market.

How large is the trimethoprim hydrochloride market?

Public company filings generally do not report trimethoprim hydrochloride revenue separately. Revenue is typically aggregated into broader categories such as generic antibiotics, anti-infectives, hospital products, or the sulfamethoxazole-trimethoprim franchise.

The standalone trimethoprim market is materially smaller than the market for the combination product. Several factors limit its value:

Trimethoprim is off patent.
Multiple manufacturers can produce the active ingredient and finished dosage forms.
Payers treat the product as a low-cost generic.
Treatment guidelines increasingly favor narrow-spectrum prescribing only where susceptibility and clinical circumstances support it.
The largest commercial demand is concentrated in established generic channels rather than branded innovation.

Market value is therefore better assessed through volume, channel share, and supply position than through brand-level pricing power.

What drives demand?

Demand is linked to:

Urinary tract infection incidence.
Pediatric outpatient prescribing.
Local antimicrobial-resistance patterns.
Availability of alternative antibiotics.
Hospital formulary decisions.
Public-health stewardship policies.
Manufacturing continuity for oral liquids and combination products.

The most defensible demand segment is outpatient urinary tract infection treatment, although resistance to trimethoprim varies by geography and pathogen. The product remains clinically useful where local susceptibility supports treatment and where beta-lactam, fluoroquinolone, or other alternatives are less suitable.

What is the FDA regulatory status of trimethoprim hydrochloride?

Trimethoprim is an FDA-recognized antibacterial active ingredient used in approved prescription products. FDA-approved products include oral tablets and oral solutions, while trimethoprim-sulfamethoxazole products have a broader range of dosage forms and manufacturers.

FDA regulatory considerations include:

Regulatory issue	Status
Active ingredient	Established antibacterial
Approval pathway	NDA legacy products and ANDA generic products
Current new-drug exclusivity	None of commercial significance
Orphan exclusivity	Not applicable to standard indications
Pediatric exclusivity	No active market-wide exclusivity identified
Biosimilar pathway	Not applicable; trimethoprim is a small molecule
Prescription status	Prescription antibacterial
FDA review risk	Primarily manufacturing, bioequivalence, labeling, and supply compliance

The main regulatory risks are product-specific. They include manufacturing observations, dissolution or assay failures, container-closure issues, microbiological contamination in liquids, and supply interruptions. These risks can affect individual manufacturers without changing the overall patent position.

What is the Orange Book status of trimethoprim hydrochloride?

Trimethoprim hydrochloride products are not protected by an active branded patent estate comparable to recently launched antibiotics. Any Orange Book-listed patents, if present for a particular product, must be assessed at the individual NDA level because listings can vary by formulation and sponsor.

The commercial conclusion is clear: trimethoprim is an established generic active ingredient, and generic competition is legally available. Orange Book strategy is therefore relevant mainly to specific branded or reformulated products, not to the basic active ingredient.

A product-level review should distinguish among:

Trimethoprim tablets.
Trimethoprim oral solution.
Sulfamethoxazole-trimethoprim tablets.
Sulfamethoxazole-trimethoprim suspension.
Any extended-release or specialty formulation.

Patent listings for a combination product do not automatically protect a standalone trimethoprim hydrochloride product.

What patents protect trimethoprim hydrochloride?

No commercially meaningful basic compound patent remains in force for trimethoprim hydrochloride. The active ingredient has been used clinically for decades, and the relevant foundational exclusivity expired long ago.

Potential residual patent categories are limited to:

Patent category	Current commercial relevance
Composition of matter	Effectively expired
Salt-form patents	No meaningful barrier for established trimethoprim hydrochloride
Tablet formulation	Possible only for a specific proprietary formulation
Oral-liquid formulation	Potentially relevant to excipients, dosing, or device combinations
Method of treatment	Narrow and vulnerable where indications are established
Manufacturing process	May protect a particular process, but usually does not block alternative production
Combination-product formulation	Relevant to sulfamethoxazole-trimethoprim products, not necessarily standalone trimethoprim

Method-of-use patents have limited economic value because the main uses of trimethoprim are long established. A manufacturer could also challenge validity, enforceability, or infringement of a narrow formulation or process patent through an ANDA Paragraph IV certification if the relevant patent were listed against the reference product.

When does trimethoprim hydrochloride lose exclusivity?

Trimethoprim lost practical market exclusivity decades ago. It is not approaching a future loss-of-exclusivity event in the manner of a branded small molecule launched within the past 20 years.

The relevant exclusivity timeline is:

Event	Timing
Original clinical development and approval	Historical
Foundational compound exclusivity	Expired
Generic entry	Established
Current market status	Multi-source generic
Future loss-of-exclusivity event	None of material significance

The commercial question is no longer whether generic entry will occur. It is whether a manufacturer can maintain supply, secure contracts, and differentiate a finished product through availability, packaging, pediatric dosing, or channel execution.

Are there Paragraph IV challenges involving trimethoprim hydrochloride?

Paragraph IV litigation is unlikely to be a major market driver for conventional trimethoprim products because the foundational patents have expired and the products are already generic.

Paragraph IV risk could arise for:

A newly approved branded oral-liquid formulation.
A proprietary delivery system.
A fixed-dose combination with a later-expiring formulation patent.
A device-enabled product.
A reformulation with a specific Orange Book-listed patent.

For standard trimethoprim tablets and established oral solutions, ANDA competition is more likely to proceed through ordinary generic approval than through high-value patent litigation.

What is the competitive landscape for trimethoprim hydrochloride?

Competition occurs across three levels.

Active pharmaceutical ingredient suppliers

Trimethoprim API production is subject to the same pressures affecting mature generic antibiotics:

Low unit prices.
Dependence on efficient chemical synthesis.
Regulatory qualification of manufacturing sites.
Concentration of production in cost-competitive regions.
Inventory requirements for critical intermediates.
Exposure to freight, energy, and solvent costs.

API suppliers with multiple qualified facilities, strong analytical documentation, and reliable delivery can command greater strategic value than suppliers competing solely on price.

Finished-dose manufacturers

Finished-dose competition is strongest in standard tablets. Oral solutions can be less commoditized because they require additional controls for taste, stability, preservative systems, dosing accuracy, and microbiological quality.

Relevant competitors may include large generic manufacturers, specialty generic companies, hospital suppliers, and contract manufacturers. Company-level revenue is generally reported at the portfolio level, so trimethoprim-specific market shares are not normally disclosed.

Therapeutic substitutes

Trimethoprim competes with:

Nitrofurantoin.
Fosfomycin.
Beta-lactam antibiotics.
Fluoroquinolones in selected settings.
Other agents selected according to susceptibility and patient factors.

For urinary tract infections, local resistance patterns can shift prescribing away from trimethoprim even when the product remains inexpensive. This creates a clinical substitution risk independent of patent expiry.

How strong is the patent estate for trimethoprim hydrochloride?

The patent estate is weak for the core molecule and conventional dosage forms.

Estate component	Strength	Commercial implication
Core molecule	Very low	Open generic competition
Salt form	Low	Limited blocking power
Standard tablet	Very low	Price-based competition
Oral solution	Low to moderate if narrowly formulated	Possible niche differentiation
Manufacturing process	Low to moderate	Protects process economics, not the market broadly
Method of use	Low	Established indications limit scope
Combination product	Product-specific	Greater relevance only where formulation patents remain

The strongest practical protection is operational rather than legal. A company with dependable supply, validated manufacturing, strong wholesaler relationships, and approved pediatric liquid capacity can outperform a nominally equivalent competitor.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are more important than patent barriers. Key risks include:

API sourcing interruptions.
Failure to qualify alternative suppliers.
Impurity control in chemical synthesis.
Dissolution variability in tablets.
Microbial contamination in oral liquids.
Stability failures under temperature stress.
Packaging shortages.
FDA inspection findings.
Changes in manufacturing sites requiring regulatory filings.

For oral liquids, taste masking and suspension uniformity can improve commercial positioning but may not create a durable barrier unless protected by a valid, enforceable formulation patent or trade secret process.

Trade secrets may protect manufacturing know-how, but they do not prevent competitors from developing an independent process. Regulatory filings also create practical switching costs because each manufacturer must establish compliance, bioequivalence where required, and product quality.

What is the financial trajectory of trimethoprim hydrochloride?

The financial trajectory is mature to declining on a price-adjusted basis, with periodic increases in market value caused by shortages rather than structural demand growth.

Financial driver	Expected effect
Generic price erosion	Persistent negative pressure
Stable infection demand	Supports baseline volume
Combination-product utilization	Supports broader market value
Pediatric liquid shortages	Can temporarily raise pricing
API cost inflation	Compresses margins
Hospital tenders	Reduces price and increases volume pressure
Supply disruption	Can create temporary revenue spikes
New formulation launch	Potential niche growth
Antimicrobial stewardship	Limits unnecessary use

A manufacturer’s revenue can rise even while the underlying market declines if it gains a supply contract, replaces a discontinued competitor, or benefits from a shortage. Those gains are usually episodic. Sustained growth would require a differentiated formulation, a new delivery technology, geographic expansion, or a broader anti-infective portfolio.

Revenue exposure for generic manufacturers

Trimethoprim typically represents a small portion of total revenue for diversified generic companies. The largest financial exposure is usually indirect:

Loss of a hospital contract.
Inability to supply a preferred generic.
Recall of an oral liquid.
API disruption affecting sulfamethoxazole-trimethoprim products.
Margin erosion from aggressive tender pricing.
Regulatory action at a manufacturing site.

The combination product can have greater portfolio importance than standalone trimethoprim because it serves more indications and has broader distribution.

What generic launch scenarios exist?

Base case: continued low-price competition

Multiple manufacturers remain active. Prices decline gradually, and value shifts toward manufacturing scale and distribution reliability.

Shortage-driven case: temporary pricing expansion

A recall, API disruption, or discontinuation removes suppliers. Remaining manufacturers gain volume and may obtain higher prices until supply normalizes.

Differentiated-formulation case: niche growth

A company launches an improved pediatric liquid, packaging system, or dose-delivery format. Revenue increases through product differentiation, but the market remains exposed to generic substitution.

Substitution case: clinical share loss

Resistance patterns, guideline changes, or greater use of alternative antibiotics reduce trimethoprim prescribing in certain markets. Volume declines without any patent event.

Does trimethoprim hydrochloride have biosimilar risk?

No. Biosimilars apply to biologic products. Trimethoprim hydrochloride is a chemically synthesized small molecule and competes through generic-drug pathways, including ANDAs in the United States and equivalent procedures in other jurisdictions.

The relevant competitive threat is generic substitution, not biosimilar entry.

What licensing deals affect trimethoprim hydrochloride?

No major current licensing transaction is central to the standalone trimethoprim hydrochloride market. The product is commercially mature, and the economic model generally relies on generic manufacturing and distribution rather than branded licensing.

Licensing may arise around:

Regional distribution rights.
Hospital supply contracts.
Contract manufacturing.
Combination-product portfolios.
Formulation technology.
Anti-infective portfolio acquisitions.

These arrangements are usually not disclosed at the trimethoprim product level.

What patent litigation affects trimethoprim hydrochloride?

There is no major current patent-litigation narrative surrounding the basic active ingredient. Litigation risk is product-specific and would most likely involve:

A branded reformulation.
A combination product.
A narrow oral-liquid patent.
A process patent.
FDA regulatory exclusivity disputes.
Antitrust claims involving supply or distribution.

For standard generic trimethoprim, operational and regulatory disputes are more commercially relevant than patent litigation.

How does trimethoprim compare with sulfamethoxazole-trimethoprim?

Metric	Trimethoprim hydrochloride	Sulfamethoxazole-trimethoprim
Product type	Single active ingredient	Fixed-dose combination
Main use	Selected urinary and bacterial infections	Broader antibacterial use
Market size	Smaller	Larger
Competition	Generic	Generic
Patent position	Mature and weak	Mature, product-specific
Clinical substitution	High in some indications	Also exposed to resistance and alternatives
Commercial differentiation	Limited	More formulation and dosage-form opportunities
Financial upside	Low without reformulation	Higher portfolio relevance

The combination product generally has stronger commercial visibility because it has broader prescribing history and more dosage forms. It also carries combination-specific manufacturing and quality obligations.

What geographic markets offer the best opportunity?

Geographic opportunity depends on local registration, resistance patterns, procurement systems, and manufacturing economics.

Geography	Market characteristics
United States	Mature generic market; strong payer and wholesaler price pressure
Europe	Established generic use; country-specific reimbursement and tender dynamics
Emerging markets	Greater volume potential; variable regulatory standards and pricing
Hospital-driven markets	Contract concentration and supply reliability matter
Pediatric markets	Oral-liquid availability can create niche value

The strongest opportunity is usually not a high-price market. It is a market where a manufacturer can register efficiently, maintain supply, and avoid crowded tender competition.

Key Takeaways

Trimethoprim hydrochloride is a mature generic antibacterial with no meaningful remaining core patent exclusivity.
Standalone revenue is generally not disclosed by manufacturers and is smaller than the sulfamethoxazole-trimethoprim market.
Generic competition, price erosion, and antimicrobial substitution constrain long-term financial growth.
Oral liquids, pediatric products, supply reliability, and hospital contracting provide the main commercial differentiation.
There is no biosimilar pathway; the relevant threat is generic substitution.
Paragraph IV litigation and major patent disputes are unlikely for conventional trimethoprim products.
Manufacturing continuity and regulatory compliance are more important than patent strength.
Temporary revenue increases are most likely during shortages, recalls, or competitor exits.
Long-term upside requires a differentiated formulation, regional expansion, or integration into a broader anti-infective portfolio.

FAQs

Is trimethoprim hydrochloride still under patent?

No meaningful basic-molecule patent protection remains. Any current patent issue would relate to a specific formulation, manufacturing process, combination product, or branded delivery system.

Is trimethoprim hydrochloride the same as trimethoprim?

Trimethoprim hydrochloride is a salt form of trimethoprim used in pharmaceutical products. Regulatory and commercial analysis generally focuses on the trimethoprim active moiety.

Can generic manufacturers enter the trimethoprim hydrochloride market?

Yes. The conventional tablet and oral-solution markets are established generic markets, subject to applicable regulatory approval, quality, bioequivalence, and manufacturing requirements.

Why can trimethoprim prices rise despite expired patents?

Prices can increase temporarily when manufacturers discontinue products, experience recalls, lose API supply, or face manufacturing disruptions. These increases reflect supply concentration rather than renewed patent exclusivity.

Is trimethoprim hydrochloride a growth pharmaceutical asset?

It is generally a maintenance or portfolio product, not a high-growth asset. Its value comes from reliable volume, efficient production, hospital access, and supply continuity rather than innovation-based pricing.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
National Library of Medicine. (n.d.). DailyMed: Trimethoprim and sulfamethoxazole and trimethoprim drug labels. U.S. National Library of Medicine.
U.S. Food and Drug Administration. (2017). Antibacterial therapies for patients with serious bacterial infections associated with limited treatment options: Guidance for industry. FDA.
World Health Organization. (2023). WHO bacterial priority pathogens list, 2024. World Health Organization.
U.S. Food and Drug Administration. (n.d.). Generic drug facts. FDA.

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	15
Clinical Trials:	203
What excipients (inactive ingredients) are in TRIMETHOPRIM HYDROCHLORIDE?	TRIMETHOPRIM HYDROCHLORIDE excipients list
DailyMed Link:	TRIMETHOPRIM HYDROCHLORIDE at DailyMed

Summary for TRIMETHOPRIM HYDROCHLORIDE

Recent Clinical Trials for TRIMETHOPRIM HYDROCHLORIDE

Anatomical Therapeutic Chemical (ATC) Classes for TRIMETHOPRIM HYDROCHLORIDE